Study Evaluating SCA-136 in Subjects With Acute Exacerbations of Schizophrenia

NCT00265551 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: SCA-136 (200 mg)
DRUG: SCA-136 (400 mg)
DRUG: olanzapine (15 mg)
DRUG: placebo

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer